NASDAQ$ARDX
Ardelyx Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported strong financial results driven by continued growth of IBSRELA and XPHOZAH.
Ardelyx reported a net loss of $0.8 million for Q3 2024, with total revenue of $98.2 million, driven by strong product sales of IBSRELA and XPHOZAH. The company ended the quarter with approximately $190.4 million in cash, cash equivalents, and investments.
- IBSRELA generated $40.6 million in net product sales, reflecting a 15% quarter-over-quarter growth.
- XPHOZAH generated $51.5 million in net product sales, demonstrating a 39% quarter-over-quarter growth.
- Total revenue for the quarter was $98.2 million, compared to $56.4 million in the same period last year.
- The company amended its loan agreement with SLR Capital Partners, drawing $50 million and extending the interest-only period.
Headline financials
Revenue & EPS history
Ardelyx · Revenue · Quarterly
$98.2M
Revenue by segment
Ardelyx · $35M total across 1 segment · Q4 2022
- Licensing Revenue$35M—100.0%
Forward guidance
Ardelyx expects full-year 2024 IBSRELA net sales revenue to be between $145 and $150 million.
Tailwinds
- Continued strong performance of IBSRELA.
- Growing demand for XPHOZAH.
- Amendment of loan agreement with SLR Capital Partners.
- Significant presence at ACG 2024.
- Publication of review article on IBS-C.
Headwinds
- CMS’ planned change in Medicare Part D reimbursement in early-January 2025.
- Uncertainties associated with the development of drugs in the U.S. and internationally.
- Increased selling, general and administrative expenses.
- Net loss for the quarter.
- Risk of dehydration in pediatric patients with IBSRELA.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+0.0%
Avg return
Earnings day
+2.6%
Avg return
5 days after
+5.2%
Avg return
30 days after
40%
20 / 50 earnings
Positive
+31.9%
Q1 2024
Best reaction
-24.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.2% | +12.2% | -4.7% | |
| Q4 2025 | -14.9% | -2.7% | -21.2% | |
| Q3 2025 | +18.6% | +18.8% | +15.8% | |
| Q1 2025 | -24.8% | -32.4% | -32.9% | |
| Q4 2024 | -10.1% | -18.6% | -19.3% | |
| Q3 2024 | +3.4% | -2.9% | -3.7% | |
| Q2 2024 | +9.0% | +9.5% | +11.4% | |
| Q1 2024 | +31.9% | +40.8% | +3.8% | |
| Q4 2023 | +2.1% | +13.8% | -9.4% | |
| Q3 2023 | +8.8% | +11.0% | +24.6% | |
| Q2 2023 | +4.2% | -2.3% | +25.5% | |
| Q1 2023 | +5.9% | -5.6% | -20.7% | |
| Q4 2022 | +30.8% | +34.9% | +64.0% | |
| Q3 2022 | +0.7% | -11.6% | +25.9% | |
| Q2 2022 | +11.5% | +14.9% | +42.5% | |
| Q1 2022 | -10.7% | -20.3% | -26.0% | |
| Q4 2021 | -7.6% | +17.0% | +37.1% | |
| Q3 2021 | -3.4% | -12.1% | +25.9% | |
| Q2 2021 | -1.3% | -9.9% | -10.5% | |
| Q1 2021 | +0.6% | +1.1% | +0.5% | |
| Q4 2020 | -4.8% | +4.5% | +14.2% | |
| Q3 2020 | -6.3% | +1.9% | +10.3% | |
| Q2 2020 | +1.4% | -2.6% | +0.7% | |
| Q1 2020 | +2.2% | +5.0% | -4.2% | |
| Q4 2019 | -7.3% | -9.1% | -12.6% | |
| Q3 2019 | +2.2% | +12.5% | +22.1% | |
| Q2 2019 | -3.8% | -5.1% | +108.1% | |
| Q1 2019 | -4.7% | -4.1% | -22.3% | |
| Q4 2018 | +8.0% | +9.7% | +9.0% | |
| Q3 2018 | -6.7% | -10.6% | -29.4% | |
| Q2 2018 | -7.1% | +0.0% | -7.1% | |
| Q1 2018 | +0.0% | +2.5% | -24.8% | |
| Q4 2017 | -5.0% | -4.5% | -6.2% | |
| Q3 2017 | +2.2% | +4.5% | +8.2% | |
| Q2 2017 | +11.0% | +17.2% | +29.9% | |
| Q1 2017 | -2.2% | -0.8% | -63.4% | |
| Q4 2016 | -2.4% | -1.1% | +13.7% | |
| Q3 2016 | +2.5% | +25.6% | +21.3% | |
| Q2 2016 | -0.8% | -1.9% | +5.8% | |
| Q1 2016 | -0.5% | — | — | |
| Q4 2015 | -5.6% | — | — | |
| Q3 2015 | -4.4% | — | — | |
| Q2 2015 | -2.8% | — | — | |
| Q1 2015 | -0.4% | — | — | |
| Q1 2014 | -0.4% | — | — | |
| Q4 2014 | -5.2% | — | — | |
| Q3 2013 | -5.5% | — | — | |
| Q3 2014 | -5.5% | — | — | |
| Q2 2013 | -1.3% | — | — | |
| Q2 2014 | -5.2% | — | — | |
| Q4 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro